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We have developed a mutation detection methodology, the solid-phase minisequencing technique, which meets the criteria of a large-scale testing system. The method is based on amplification of the DNA fragment spanning the mutation under study by using a 5'-biotinylated PCR primer, binding of the amplification product on a streptavidin-coated matrix, and primer-guided single-nucleotide incorporation at the site of the mutation [2] . The method is robust, quantitative, reliable, and easily automated, and can be adapted for use with nonradioactive labels [3] . A double-labeling system for the simultaneous detection of two different mutations has also been developed [2] . The minisequencing method is at present routinely applied for detection of >15 inherited or somatic mutations [4] [5] [6] [7] [8] [9] .
It has also been utilized in the detection of mutations causing CF [10] , in detection of minor malignant cell populations [11] , and in forensic identification of individuals [12] . The The disease is clinically characterized by severe mental retardation, susceptibility to infections, and various mild connective tissue manifestations [19] . The carrier frequency of the disease is 1:50-1:70, with regional differences [20] . The predominant mutation (AGUFIfl major), which is responsible for 98% of the disease alleles, is a point mutation (G488 -* C) causing a substitution of cysteine to serine (Cys163 -Ser) [4, 21] . In addition, another rare mutation (AGUF minor) has recently been identified in seven Finnish AGU patients. This 2-bp deletion in the second exon of the AGA gene results in a frameshift and premature termination of translation [22] . All of these patients are compound heterozygotes with the AGUFI, major mutation in one allele and the AGUFfl minor mutation in the other. Over 99% of the Finnish AGU alleles can be detected with a search for these two mutations.
The combination of the two phenomena, a well-designed mutation detection protocol and the existence of one major disease-causing mutation, made a health center-based carrier screening program tempting. In the present paper we report the applicability and accuracy of the minisequencing method in large-scale carrier screening of AGU in which 2000 pregnant women and the spouses of identified carriers were offered the screening test at maternity healthcare offices. The general outline of the project and the attitudes of the mothers and healthcare personnel will be reported separately.
Materials and Methods

CARRIER SCREENING
PROGRAM
The gene test for AGU was offered to women at early pregnancy (mainly before 12 weeks of pregnancy) in two health centers in Helsinki, with a total of 13 maternity care units. Before the screening, training was organized for the personnel of maternity care units and laboratories of health centers, including basic knowledge in gene testing in general, AGU disease, and the whole screening program. Information on the gene test was mailed to the mothers after they had booked the first appointment at the maternity healthcare unit. At the first visit, the women who had decided to participate gave written consent, and blood samples were taken either during the first visit by nurses or after the visit in laboratories of the health centers. Only partners of the women identified as carriers were tested (stepwise screening).
The test was conducted once a week, or when necessary in urgent cases. The test results were mailed to the noncarrier mothers and given personally by telephone by one of the authors (M.H.) to the carriers. The study protocol was approved by the Ethical Committees of the University of Turku, the National Public Health Institute, and the city of Helsinki.
BLOOD SAMPLES
Blood spots were collected on a dry blank strip (Merckoquant 11860; Merck, Darmstadt, Germany; similar to urine test dipsticks), with a 0.6 X 0.6 cm2 area of blotting paper (Fig. 1) . The samples were taken either by dropping capillary blood directly onto the strip from the fingertip, or by dipping the strip in a tube of EDTA-blood, if a venous blood sample was taken for other purposes.
Two blood strips were collected from each participant.
The blood spots were dried and mailed to the laboratory in sterile marked plastic bags. The samples were stable for at least 18 months at room temperature.
DATA STORAGE
During the course of the study the following data storage protocol was developed. When reaching the Helsinki University Central Hospital Laboratory Department, the samples and test requests were entered into the laboratory computer system (Multilab 1; Mylab, Tampere, Finland), which produced bar codes corresponding to each sample. The bar codes were used to prepare a worklist, which was utilized in all subsequent steps of the analysis. After the completion of the analysis, the Multilab program presented a list of the test results, which was faxed to the clinical geneticist of the screening team. The DNA of the blood spot is amplified with one biotinylated and one unbiotinylated primer spanning the mutation, and the amplification product is captured into streptavidin-coated scintillation microtitration plate wells and subsequently denatured. The nucleotides at the mutation site are identified by two separate reactionswith primer-guidedsingle nucleotideincorporation.The radioactivityof the wells is counted in a scintillation counter, and the result for each sample is obtained by using the ratio of mutation-specific nucleotide to normal nucleotide incorporation (R value).
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DNA AMPLIFICATION AND PRIMERS
The oligonucleotides were synthesized on an Applied Biosystems (Foster City, CA) 381A DNA synthesizer.
The primers for the amplification (PCR1 and PCR2) and detection (Dl) of the AGUFfl major mutation have been described previously [4] 
INTERNAL CONTROLS
A sample from one volunteer heterozygote AGUFIfl major carrier and one normal homozygote were included in each microplate.
These two control individuals remained the same throughout the study period. The control samples were treated identically to the patients' samples. Control samples from one homozygous normal and one heterozygous individual were also used in the assays for the AGUFIfl minor mutation. In addition, negative controls (no sample) for PCR and the miisequencing reaction were included in each plate.
Results
Altogether
1975 women of the 2077 who were offered the gene test (95%) chose to participate.
Carriers (31) of the AGUFfl major mutation were detected (carrier frequency 1:64, 95% confidence interval 1:98 to 1:47). All of the spouses of the carrier women were normal.
About 40% of the samples were collected directly from the fingertip in the maternity offices, and the rest of the samples were obtained by dipping the strip into EDTA-blood in the laboratories.
Despite the fact that many blood spots were very small,only one of the fingertip samples was inadequate for PCR, and a new sample had to be requested.
The result of the minisequencing-based DNA test is expressed in R values (cpmmutlcpmno,.,,J.
This facilitates easy interpretation of test results and data storage. The mean R value for the 104 consecutive assays of the normal control was 0.026 (range 0.004-0.066), and for the study samples identified as noncarriers (1944 women, 31 spouses) the mean R value was 0.028 (range 0.001-0.084) ( Table  1) . For the heterozygote control sample the mean R value (103 assays) was 0.56 (range 0.28-0.99), and 0.53 (range 0.35-0.69) for the subjects identifled as carriers (n = 31). Thus the R values fell into two clearly distinct categories with no overlap (Figs. 2 and 3) , and the carriers could be distinguished from the normal homozygotes by a 19-fold increase in the average R value.
The reproducibility of the assay during the 1-yearperiod was 1401 assays performed and is presented in Table 1 and Fig. 2 . The variation between assays was estimated on the basis of both the mean of R values of noncarriers in each run and of the R value of the carrier and normal controls, and the follow-up chart is presented in Fig. 3 The difference in R value between the carriers and normal homozygotes was thus -30-fold for the detection of the AGUFfl minor mutation.
The complete testing procedure took -9 h per series containing 39 samples on average. Sample coding took 1 h, preparation of the blood spots for PCR 2.5 h, the minisequencing assay 4 h, and the checking and reporting of the results 1.5 h. Thus the assay was in most cases performed during two working days. The first day included preparation, coding, and PCR amplification of the samples; the minisequencing took place during the second day. The cost of the reagents for one sample was -$5 (US) and the cost of labor $7, thus giving a total cost of $12 per sample for the laboratory part of the screening. All samples from the identified carriers were retested in the next analysis series to confirm the results. Because of analytical difficulties, the repeat rate for the test for the AGUFfl major mutation was 2.5% (n = 44). Of these 44 samples, a failure of amplification was the reason for reanalysis in 24 samples, but reamplification of the same original blood sample from a second strip was successful in all these cases. Disproportion between the two parallel cpm values for the mutation-specific nucleotides required retesting of 20 samples. All of them proved to be normal homozygotes.
The precise reason for this discrepancy remains unclear, but contamination of radioactivity from the neighboring well might be one cause. Also, moisture or static electricity on a plastic seal disturb the detection by altering the light path to the detectors of the scintillation counter.
Discussion
A laboratory method to be used in population-based screening for disease-causing gene defects has to meet stringent specifications. The DNA test must be reliable, simple, rapid, and inexpensive, and, preferentially, the data should be storable in a numeric format. Here we have demonstrated the application of a simple, reliable, and robust mutation detection system in a pilot population-screening program. The minisequencing procedure, combined with both efficient and easy sampling and efficient sample coding procedures available in large laboratories, proved to facilitate economical and reliable genetic screening.
A large-scale genetic screening program involves personnel from three different disciplines:
primary healthcare, the testperforming laboratory, and clinical genetics. A good collaboration between these groups is an essential prerequisite for the success of the program. Here we have evaluated the role of the clinical laboratory and shown that not only the technical facilities and knowledge but also good contacts with healthcare workers and clinical geneticists must exist.
Furthermore, it is essential that the coverage of the test, or multiple tests, is sufficient to yield a high detection rate of the gene defects causing the disease in the population to be screened. In this respect genetic heterogeneity, i.e., several gene defects causing the same disease, is a problem. Isolated populations with a relatively homogeneous gene pool are in a more favorable position in this respect than mixed populations showing a higher degree of genetic heterogeneity. [23] and from beta-thalassemias in Mediterranean populations [24] . In both cases, however, the testing was based mainly on protein assays, namely hexosaminidase A activity and hemoglobin, respectively, thus alleviating the problems due to genetic heterogeneity. DNA tests detecting several mutations have recently been developed for these diseases as well, and are utilized in carrier screening with detection rates and costs comparable with the conventional tests [24, 25] . The interest towards large-scale carrier screening has recently been focused especially on CF, the most common single-gene disease among Caucasian populations. CF carrier screening in most populations is complicated by the diversity of the mutations, but kits capable of detecting several mutations have recently been developed [26] [27] [28] , and are being utilized in pilot screening programs with detection frequencies -90% [29] [30] [31] [32] .
There is a variety of PCR-based methods for detection of known mutations.
These include hybridization with allelespecific oligonucleotide probes (ASO) [33] ; restriction site variation analysis (RFLP), either based on mutation-specific RFLPs [34] or by creating restriction sites with allele-specific primers [35] ; and the amplification refractory mutation system (ARMS) [36] . for carrier screening identical to those in AGU. In the near future, the disease-causing mutations in several other "Finnish" genetic diseases will be identified, thus increasing the interest in genetic testing. The high participation rate in the present study, and mainly positive attitudes among the general population toward genetic testing in Finland, as indicated in our earlier study [38] , predict acceptance of future screening programs as well.
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